Cannabidiol-containing aerosol inhalant and application thereof

Abstract

The invention discloses an aerosol inhalant containing cannabidiol and application of the aerosol inhalant. The aerosol inhalant is prepared from the following components: 3.0 to 5.0 g of cannabidiol, 2.2 to 2.6 g of honeysuckle flower extract, 1.0 to 1.5 g of bamboo leaf extract, a proper amount of water for injection and 9.0 to 15.0 g of glycerol, and the volume of the water for injection is fixed to 1000ml. The aerosol inhalant can be used for preventing and treating sphagitis.

Description

Technical Field

[0001] This invention belongs to the field of cannabidiol preparation technology, specifically, it relates to a cannabidiol-containing nebulized inhaler and its application. Background Technology

[0002] Cannabidiol (CBD) is a natural component extracted from industrial hemp. It is widely used in the pharmaceutical, health product, and cosmetic industries. CBD possesses antioxidant, sedative, antidepressant, anti-inflammatory, and vasodilatory effects. It is non-hallucinogenic and non-addictive, and is a novel drug for the clinical treatment of breast cancer and epilepsy.

[0003] The incidence of pharyngitis is increasing year by year due to factors such as environmental pollution, unhealthy lifestyle habits such as smoking and excessive drinking, and excessive use of the voice such as singing and lecturing for long periods of time. Summary of the Invention

[0004] In order to overcome the problems existing in the prior art, the present invention proposes a cannabidiol-containing nebulized inhaler and its application.

[0005] To achieve the above objectives, the present invention is implemented through the following technical solution: The first aspect of the present invention provides a cannabidiol-containing nebulized inhalant, comprising the following components: 3.0-5.0g of cannabidiol, 2.2-2.6g of honeysuckle extract, 1.0-1.5g of bamboo leaf extract, an appropriate amount of water for injection, 9.0-15.0g of glycerol, and water for injection diluted to 1000ml.

[0006] A second aspect of the present invention provides the application of the above-mentioned nebulized inhalant in the prevention and treatment of pharyngitis.

[0007] A third aspect of this invention provides a method for preparing a cannabidiol-containing nebulized inhalant, comprising the following steps: S1, add honeysuckle extract to an appropriate amount of water for injection, stir until fully dissolved, and obtain mixture A; S2, add cannabidiol to glycerol and stir until fully dissolved to obtain mixture B; S3. Mix mixtures A and B thoroughly, then add bamboo leaf extract, stir well, add water for injection to bring the volume to 1000ml, then sterilize the mixture using ultraviolet radiation sterilization and dispense to obtain the nebulized inhalant.

[0008] Through the above technical solution, the present invention can achieve at least the following beneficial effects: The inventors of the present invention have discovered that dissolving and mixing cannabidiol, honeysuckle extract, and bamboo leaf extract in an alcohol-water system and then nebulizing the mixture and administering it to the throat can prevent and treat pharyngitis. Detailed Implementation

[0009] Unless otherwise stated, all materials and reagents used in this invention are commercially available.

[0010] In this invention, the honeysuckle extract was purchased from Shandong Gushuo Biotechnology Co., Ltd., the bamboo leaf extract was purchased from Baoji Liupanyun Biotechnology Co., Ltd., and the glycerol was purchased from Shandong Dengnuo New Material Technology Co., Ltd.

[0011] Example 1 A cannabidiol-containing nebulized inhaler comprises the following components: 3.5g cannabidiol, 2.5g honeysuckle extract, 1.3g bamboo leaf extract, appropriate amount of water for injection and 12.0g glycerol, with the water for injection diluted to 1000ml.

[0012] The preparation method of the above-mentioned nebulized inhalant includes the following steps: S1, add honeysuckle extract and bamboo rhizome extract to water for injection, stir until fully dissolved, and obtain mixture A; S2, add cannabidiol to glycerol and stir until fully dissolved to obtain mixture B; S3. Mix mixtures A and B thoroughly, then add bamboo leaf extract, stir well, sterilize the mixture using ultraviolet radiation sterilization, and then dispense it to obtain the nebulized inhalant.

[0013] Example 2 A cannabidiol-containing nebulized inhaler comprises the following components: 3.0g cannabidiol, 2.2g honeysuckle extract, 1.0g bamboo leaf extract, appropriate amount of water for injection and 9.0g glycerol, with the water for injection diluted to 1000ml.

[0014] The preparation method of the above-mentioned nebulized inhalant includes the following steps: S1, add honeysuckle extract to water for injection, stir until fully dissolved, and obtain mixture A; S2, add cannabidiol to glycerol and stir until fully dissolved to obtain mixture B; S3. Mix mixtures A and B thoroughly, then add bamboo leaf extract, stir well, sterilize the mixture using ultraviolet radiation sterilization, and then dispense it to obtain the nebulized inhalant.

[0015] Example 3 A cannabidiol-containing nebulized inhaler comprises the following components: 4.0g cannabidiol, 2.4g honeysuckle extract, 1.2g bamboo leaf extract, appropriate amount of water for injection and 12.0g glycerol, with the water for injection diluted to 1000ml.

[0016] The preparation method of the above-mentioned nebulized inhalant includes the following steps: S1, add honeysuckle extract to water for injection, stir until fully dissolved, and obtain mixture A; S2, add cannabidiol to glycerol and stir until fully dissolved to obtain mixture B; S3. Mix mixtures A and B thoroughly, then add bamboo leaf extract, stir well, sterilize the mixture using ultraviolet radiation sterilization, and then dispense it to obtain the nebulized inhalant.

[0017] Example 4 A cannabidiol-containing nebulized inhaler comprises the following components: 5.0g cannabidiol, 2.6g honeysuckle extract, 1.5g bamboo leaf extract, appropriate amount of water for injection and 15.0g glycerol, with the water for injection diluted to 1000ml.

[0018] The preparation method of the above-mentioned nebulized inhalant includes the following steps: S1, add honeysuckle extract to water for injection, stir until fully dissolved, and obtain mixture A; S2, add cannabidiol to glycerol and stir until fully dissolved to obtain mixture B; S3. Mix mixtures A and B thoroughly, then add bamboo leaf extract, stir well, sterilize the mixture using ultraviolet radiation sterilization, and then dispense it to obtain the nebulized inhalant.

[0019] Comparative Example 1 The difference between Comparative Example 1 and Example 1 is that it does not contain honeysuckle extract.

[0020] Comparative Example 2 The difference between Comparative Example 2 and Example 1 is that it does not contain bamboo leaf extract.

[0021] Experimental testing I. Constructing an Acute Pharyngitis Mouse Model 1.1 Experimental Animals SPF grade rats, half male and half female (females are non-pregnant), weighing 200±10g, aged 5-6 months; the rats were housed in a shielded laboratory environment with free access to food and water, in separate cages, with frequent bedding changes, room temperature of 22-25℃, relative humidity of 60%, and ample sunlight.

[0022] 1.2 Test drug and dosage The nebulized inhalers prepared in Examples 1 to 4 and Comparative Examples 1 to 2 were administered at a dose of 2 ml / kg BW.

[0023] 1.3 Instruments and Reagents Instruments: YP / 0001 electronic animal weight balance; BT25S electronic balance (d=0.01mg); AL204 precision electronic balance; glass atomizer; small animal mouth and nose exposure system: HRH-MNE3026, manufactured by Beijing Huironghe Technology Co., Ltd. Reagent: Ammonia.

[0024] 1.4 Test Methods After one week of acclimatization, rats were randomly divided into a normal control group, a model group, Example 1-4 groups, and Comparative Example 1-4 groups, with 10 rats in each group (half male and half female). Except for the normal control group, the rats in the other groups were sprayed with 15% ammonia solution to induce an acute pharyngitis model. The spraying was performed twice a day, once in the morning and once in the afternoon, using a glass sprayer for three sprays each time, for three consecutive days. The normal control group rats were sprayed with the same amount of physiological saline solution daily using the same method. On the fourth day, the spraying was stopped. The rats in the Example and Comparative Example groups were then administered medication via nebulization using a small animal oral-nasal exposure system at the prescribed dose, once a day for four consecutive days. The normal control group and the model group were nebulized with the same amount of physiological saline solution.

[0025] 1.5 Observation Indicators After the last administration, the rats' water intake and food consumption were observed; blood was also collected from the tail vein to determine the white blood cell count (WBC). In addition, six rats were randomly selected from each group and sacrificed. The morphology and color of the pharyngeal mucosa were observed, and pathological sections of the pharyngeal mucosa and underlying tissue were prepared for observation. After routine paraffin embedding and HE staining, pathological changes were observed. The pathological state of the rat pharyngeal tissue and the corresponding scores are shown in Table 1 below.

[0026] Table 1 Correspondence between pathological state of rat pharyngeal tissue and scores 1.6 Test Results Two days after ammonia spraying, most rats in each group exhibited scratching of their mouths, increased water intake, and decreased food intake. The throat area became congested, dark red, and swollen. After administration of the test substances from Examples 1-3, the redness and swelling in the rats were reduced compared to the model group, with decreased water intake and increased food intake.

[0027] The results of rat blood routine WBC and the pathological conditions of rat pharyngeal tissue are summarized in Tables 2 and 3.

[0028] Table 2. WBC count results in the complete blood count of rats in each group (n=10) Table 3. Case score table of pharyngeal tissue of rats in each group Experimental results show that the nebulized inhalant prepared in each embodiment of the present invention can improve the symptoms of acute pharyngitis in rats, significantly improve the pathological changes in the pharynx and larynx of the rats, and significantly reduce the pathological score compared with the model group. This indicates that the nebulized inhalant of this application has a good therapeutic effect on acute pharyngitis in rats.

[0029] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made to it in form and detail without departing from the scope defined by the claims of the present invention.

Claims

1. A cannabidiol-containing aerosol inhaler, characterized in that: It contains the following components: cannabidiol 3.0-5.0g, honeysuckle extract 2.2-2.6g, bamboo leaf extract 1.0-1.5g, appropriate amount of water for injection, glycerol 9.0-15.0g, and water for injection to a final volume of 1000ml.

2. The cannabidiol-containing nebulized inhaler according to claim 1, characterized in that: It contains the following components: cannabidiol 3.5g, honeysuckle extract 2.5g, bamboo leaf extract 1.3g, appropriate amount of water for injection, glycerol 12.0g, and water for injection to a final volume of 1000ml.

3. The application of a cannabidiol-containing nebulized inhaler as described in claim 1 or 2 in the prevention and treatment of pharyngitis.

4. A method for preparing a cannabidiol-containing nebulized inhalant as described in claim 1 or 2, characterized in that, Includes the following steps: S1, add honeysuckle extract to an appropriate amount of water for injection, stir until fully dissolved, and obtain mixture A; S2, add cannabidiol to glycerol and stir until fully dissolved to obtain mixture B; S3. Mix mixtures A and B thoroughly, then add bamboo leaf extract, stir well, add water for injection to bring the volume to 1000ml, then sterilize the mixture using ultraviolet radiation sterilization and dispense to obtain the nebulized inhalant.

Images